Merz Pharmaceuticals sought provisional measures against Viatris Santé, alleging patent infringement. However, the initial application was rejected, with Merz ordered to pay interim costs. On appeal, Merz requested new evidence (Exhibit 823) be kept confidential, filing under RoP 262.2. However, the court clarified that confidentiality under RoP 262A must be requested explicitly for restrictions on opposing party’s use of info. Without proper application, documents are made accessible to other parties. Thus, Merz's confidentiality request was not immediately granted and the court ordered the exhibit's access status be changed to allow Viatris Santé access.